Locally Advanced Solid Tumor Clinical Trials

15 recruiting

Locally Advanced Solid Tumor Trials at a Glance

21 actively recruiting trials for locally advanced solid tumor are listed on ClinicalTrialsFinder across 6 cities in 21 countries. The largest study group is Phase 1 with 15 trials, with the heaviest enrollment activity in Houston, New York, and Barcelona. Lead sponsors running locally advanced solid tumor studies include Nuvalent Inc., Turning Point Therapeutics, Inc., and Centro di Riferimento Oncologico - Aviano.

Browse locally advanced solid tumor trials by phase

Treatments under study

About Locally Advanced Solid Tumor Clinical Trials

Looking for clinical trials for Locally Advanced Solid Tumor? There are currently 15 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Locally Advanced Solid Tumor trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Locally Advanced Solid Tumor clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 21 trials

Recruiting
Phase 1Phase 2

A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours

Metastatic Solid TumorLocally Advanced Solid Tumor
Ipsen114 enrolled12 locationsNCT07213817
Recruiting
Phase 1Phase 2

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

Locally Advanced Solid Tumor
Tango Therapeutics, Inc.225 enrolled26 locationsNCT05732831
Recruiting
Phase 1

AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors

Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)
Amgen464 enrolled6 locationsNCT07403721
Recruiting
Phase 2

A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor

TMB-HHistologically or Cytologically Proven Metastatic or Locally Advanced Solid Tumors
ImmuneOncia Therapeutics Inc.30 enrolled4 locationsNCT06365840
Recruiting
Phase 1

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Metastatic Solid TumorsLocally Advanced Solid TumorsRecurrent Solid Tumors
Genentech, Inc.250 enrolled18 locationsNCT06031441
Recruiting
Phase 1Phase 2

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Metastatic Solid TumorsLocally Advanced Solid Tumors
Turning Point Therapeutics, Inc.500 enrolled165 locationsNCT03093116
Recruiting
Phase 1

A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)

Metastatic Solid TumorLocally Advanced Solid Tumor
Nuvalent Inc.200 enrolled21 locationsNCT06521554
Recruiting
Phase 2

Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors

Metastatic Solid TumorLocally Advanced Solid Tumor
University of Utah25 enrolled1 locationNCT06358677
Recruiting
Phase 2

CD8 PET Imaging in Metastatic Solid Tumours

Locally Advanced Solid Tumor
University Medical Center Groningen30 enrolled4 locationsNCT06534190
Recruiting
Phase 1Phase 2

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

LymphomaMetastatic Solid TumorsLocally Advanced Solid Tumors+1 more
Turning Point Therapeutics, Inc.75 enrolled68 locationsNCT04094610
Recruiting
Phase 1Phase 2

A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer

Metastatic CancerSolid TumorUnresectable Solid Tumor+3 more
Spago Nanomedical AB90 enrolled2 locationsNCT06184035
Recruiting
Phase 1Phase 2

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

Metastatic Solid TumorLocally Advanced Solid Tumor
Nuvalent Inc.840 enrolled74 locationsNCT05384626
Recruiting
Phase 1Phase 2

A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)

Metastatic Solid TumorLocally Advanced Solid Tumor
Nuvalent Inc.359 enrolled63 locationsNCT05118789
Recruiting
Phase 1

A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab

Advanced Solid TumorCancerMetastatic Cancer+2 more
Nectin Therapeutics Ltd90 enrolled6 locationsNCT05378425
Recruiting
Phase 1Phase 2

Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors

Metastatic Solid TumorLocally Advanced Solid TumorEGFR Overexpression
Yuhan Corporation80 enrolled4 locationsNCT06975410
Recruiting
Phase 1

A Phase I Study of SIM0686 in Participants With Locally Advanced/Metastatic Solid Tumors

Locally Advanced Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.220 enrolled10 locationsNCT07050459
Recruiting
Phase 1

ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

Metastatic Solid TumorLocally Advanced Solid Tumor
Acepodia Biotech, Inc.30 enrolled9 locationsNCT06415487
Recruiting
Phase 3

Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors

Locally Advanced Solid Tumor
Jiangsu vcare pharmaceutical technology co., LTD54 enrolled1 locationNCT06658353
Recruiting
Phase 1

IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors

Locally Advanced Solid Tumor
Innovent Biologics (Suzhou) Co. Ltd.250 enrolled5 locationsNCT06349408
Recruiting
Phase 2

Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors

CancerMetastatic CancerLocally Advanced+2 more
University of Cincinnati37 enrolled1 locationNCT06416007